CON Concentra Group Holdings Parent, Inc.

CIK 0002014596 28 ready 8-Ks latest September 8, 2026, 4:42 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (4)

Ready 8-Ks 28

Latest filing September 8, 2026, 4:42 PM ET

Top materiality 0.85

Event mix earnings ×10 · other_material ×6 · other ×5

Sentiment 13 pos · 0 neg · 15 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for CON

Highest-materiality recent filing

Concentra beats 2025 guidance; Q4 revenue +15.9% to $539M, FY revenue +13.9% to $2.16B

January 28, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Q4 2025 revenue $539.1M (+15.9%), net income $36.2M (+58.7%), adjusted EBITDA $95.3M (+22.9%).
Full year 2025 revenue $2,163.4M (+13.9%), adjusted EBITDA $431.9M (+14.6%), EPS $1.30 (adj $1.37).

Read filing →

September 8, 2026, 4:42 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×3

Concentra names Tanner Newton CFO effective Nov 1, 2026

Tanner Newton, current SVP Strategy & Finance (since Jan 2025), appointed EVP & CFO effective Nov 1, 2026.
August 27, 2026, 4:50 PM ET other material materiality 0.40 neutral item 1.01 item 9.01

Concentra repurchases 1M shares from Chairman at $34.65/share for $34.65M

Repurchased 1,000,000 shares from Chairman Robert A. Ortenzio and related trusts at $34.65/share, total $34.65M.
August 6, 2026, 4:49 PM ET earnings materiality 0.80 positive item 2.02 item 5.02 item 7.01 item 8.01 item 9.01

Concentra Q2 revenue up 10%, net income up 46%; raises FY guidance; CEO succession to DiCanio

Q2 revenue $606M (+10% YoY), net income $67.3M (+45.7%), adjusted EBITDA $140.9M (+22.5%).
July 10, 2026, 4:53 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change

Concentra CMO Dr. John Anderson to retire; enters consulting agreement with equity vesting terms

Dr. John R. Anderson, EVP and CMO, retires Dec 31, 2026; consulting agreement Jan 1-Dec 31, 2027.
May 7, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 8.01 item 9.01 ◈ Earnings Releases ×2

Concentra Q1 revenue $569.6M (+13.7%); raises FY26 guidance; declares $0.0625 dividend

Revenue $569.6M (+13.7% YoY); net income $52.3M (+28.7%); EPS $0.39, adjusted EPS $0.40.
April 30, 2026, 7:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Concentra stockholders elect directors, approve say-on-pay and auditor ratification

Elected Vipin Gopal, William K. Newton, and Dr. Marc R. Watkins as Class II directors with 98%+ 'For' votes (excluding broker non-votes).
April 14, 2026, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 item 7.01 item 9.01

Concentra CMO Dr. John Anderson to retire Dec 31, 2026; consulting role planned

Dr. John Anderson, EVP and Chief Medical Officer, will retire effective December 31, 2026.
February 26, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 8.01 item 9.01

Concentra Q4 revenue +15.9% to $539M; guides FY2026 rev $2.25B-$2.35B

Q4 2025 net income $36.2M (+58.7% YoY); EPS $0.27, adjusted EPS $0.28.
January 28, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Concentra beats 2025 guidance; Q4 revenue +15.9% to $539M, FY revenue +13.9% to $2.16B

Q4 2025 revenue $539.1M (+15.9%), net income $36.2M (+58.7%), adjusted EBITDA $95.3M (+22.9%).
January 12, 2026, 6:59 PM ET other material materiality 0.30 neutral item 2.02 item 7.01 item 9.01

Concentra releases preliminary Q4 2025 operational metrics; details not provided in filing

Company published a presentation with preliminary unaudited Q4 2025 operational metrics.
November 10, 2025, 6:59 PM ET other materiality 0.40 neutral item 5.02

Concentra grants 645,000 restricted shares to six named executive officers; vest over four years

CEO W. Keith Newton received 225,000 restricted shares; CFO Matthew T. DiCanio received 180,000 shares.
November 6, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 8.01 item 9.01

Concentra Q3 revenue +17% to $572.8M, EPS $0.38, raises FY2025 guidance

Revenue $572.8M (+17% YoY); net income $49.8M; EPS $0.38; adjusted EPS $0.39.
August 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 8.01 item 9.01

Concentra Q2 revenue $550.8M (+15.2%), raises FY 2025 guidance

Q2 revenue $550.8M (+15.2% YoY), net income $46.2M, EPS $0.35, adjusted EPS $0.37.
June 26, 2025, 7:59 PM ET leadership materiality 0.30 positive item 5.02 item 7.01 item 9.01

Concentra appoints Vipin Gopal and Brigid Bonner to board, effective July 1, 2025

Vipin Gopal and Brigid Bonner appointed to Concentra board, effective July 1, 2025.
June 2, 2025, 7:59 PM ET M&A materiality 0.65 positive item 2.01 item 7.01 item 9.01 ◈ M&A Transactions

Concentra closes $55M acquisition of Pivot Onsite Innovations, doubling onsite clinics to ~350

Acquired all equity of Onsite Innovations (Pivot Onsite) for $55M, using cash and revolver.
May 7, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 8.01 item 9.01

Concentra Q1 revenue $500.8M (+7.1% YoY), Adj. EBITDA $102.7M (+6.8%), raises 2025 guidance

Net income $40.6M ($0.30 EPS); adjusted EPS $0.32, down from $0.49 YoY due to higher interest from IPO recap.
May 2, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07 item 9.01

Concentra shareholders elect two Class I directors and approve say-on-pay at 2025 annual meeting

Daniel J. Thomas elected with 112,356,457 votes for; Cheryl B. Pegus elected with 113,994,041 votes for.
April 21, 2025, 7:59 PM ET M&A materiality 0.65 positive item 1.01 item 7.01 item 9.01

Concentra to acquire Pivot Onsite Innovations for $55M; doubles onsite health segment

$55M acquisition of Pivot Onsite Innovations from Athletico Physical Therapy.
March 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 1.01 item 2.01 item 2.02 item 2.03 item 8.01 item 9.01 ◈ M&A Transactions

Concentra Q4 revenue +5.5% to $465M, adjusted EBITDA +13.6%; closes $265M Nova acquisition; declares $0.0625 dividend

Q4 revenue $465.0M (+5.5% YoY); net income $22.8M ($0.17 EPS).
January 23, 2025, 6:59 PM ET M&A materiality 0.80 positive item 1.01 item 2.02 item 9.01

Concentra to acquire Nova Medical Centers for $265M; Q4 revenue $465M (+5.5% YoY)

Agreement to buy all membership interests of Nova Medical Centers for $265M; expected close in Q1 2025.
January 15, 2025, 6:59 PM ET other materiality 0.20 neutral item 5.02

Concentra approves 2025 base salaries for named executive officers

CEO William K. Newton 2025 base salary set at $850,000.
November 29, 2024, 6:59 PM ET other material materiality 0.50 neutral item 5.02

Concentra grants 585K restricted shares to 5 named executive officers

CEO W. Keith Newton receives 225,000 shares; vests equally over 4 years.
November 26, 2024, 6:59 PM ET other material materiality 0.75 neutral item 5.01 item 9.01 ◈ M&A Transactions

Concentra completes spin-off from Select Medical; distributes 104M shares to Select stockholders

Select Medical distributed 104,093,503 shares of Concentra common stock (81.7% ownership) to its stockholders.
November 12, 2024, 6:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

Concentra furnishes investor presentation; content not disclosed in filing text

Regulation FD disclosure of a presentation for Q4 2024 investor discussions.
October 31, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 8.01 item 9.01

Concentra Q3 revenue $489.6M (+3.3%); Adj. EBITDA $101.6M; declares $0.0625 dividend

Net income $45.8M, EPS $0.37; Adjusted EBITDA margin 20.7% vs 20.9% YoY.
October 30, 2024, 7:59 PM ET other material materiality 0.55 neutral item 5.02 item 9.01

Concentra amends CFO DiCanio's employment: salary to $550K, severance extended to 18 months

Base salary increased to $550,000, effective January 1, 2024.
August 1, 2024, 7:59 PM ET other material materiality 0.80 neutral item 1.01 item 2.03 item 5.02 item 5.03 item 9.01

Concentra completes IPO, enters $1.25B credit facility and issues $650M notes

Completed IPO of 22.5M shares at $23.50/share, net proceeds ~$499.7M.
August 1, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

Concentra Q2 revenue up 2.3% to $477.9M; completed IPO on July 26

Net income $53.1M (-1.8% YoY); EPS $0.50 (-2.0% YoY); Adjusted EPS $0.49.

Executive changes

Role change

Keith Newton

Executive Chairman

CON · Concentra Group Holdings Parent, Inc.

Effective: 2026-11-01
Filed: September 8, 2026, 4:42 PM ET

As previously announced, effective November 1, 2026, (i) Matthew DiCanio, the President and Chief Financial Officer of Concentra Group Holdings Parent, Inc. (the “Company”), will serve as the Company’s President and Chief Executive Officer and (ii) Keith Newton will transition from Chief Executive Officer of the Company to serve as the Executive Chairman of the Company’s Board of Directors (“Board”).

Appointed

Tanner Newton

Executive Vice President and Chief Financial Officer

CON · Concentra Group Holdings Parent, Inc.

Effective: 2026-11-01
Filed: September 8, 2026, 4:42 PM ET

On September 8, 2026, the Company announced the appointment of Tanner Newton as Executive Vice President and Chief Financial Officer of the Company, effective November 1, 2026 (the “Effective Date”).

Role change

Matthew DiCanio

President and Chief Executive Officer

CON · Concentra Group Holdings Parent, Inc.

Effective: 2026-11-01
Filed: September 8, 2026, 4:42 PM ET

As previously announced, effective November 1, 2026, (i) Matthew DiCanio, the President and Chief Financial Officer of Concentra Group Holdings Parent, Inc. (the “Company”), will serve as the Company’s President and Chief Executive Officer and (ii) Keith Newton will transition from Chief Executive Officer of the Company to serve as the Executive Chairman of the Company’s Board of Directors (“Board”).

Departed

Dr. John R. Anderson

Executive Vice President and Chief Medical Officer

CON · Concentra Group Holdings Parent, Inc.

Effective: 2026-12-31
Filed: July 10, 2026, 4:53 PM ET

Dr. John R. Anderson notified Concentra Group Holdings Parent, Inc. (the “Company”) of his retirement from his position as Executive Vice President and Chief Medical Officer of the Company effective as of December 31, 2026.

Earnings & guidance

2026-Q1 EPS reported $0.39 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

13 positive 0 negative 15 neutral

source · CON on sec.gov